Abstract
Invasive bladder cancer is associated with a cure rate of only 50 %, when all stages are considered. The pattern of relapse is dominated by systemic spread, with metastases occurring despite local control. In the past three decades, new approaches to treatment have been predicated on the use of systemic chemotherapy before, during or after loco-regional management in an attempt to control occult systemic disease. In parallel, more aggressive surgical approaches and modified radiation techniques in association with systemic chemotherapy have been employed to secure improved local control. More recently, molecular prediction has been applied to this clinical problem, with gene expression being studied as a prognostic and predictive marker. Of particular importance, P53 mutation and expression of the epidermal growth factor receptor may predict for natural history and/or response to treatment. Novel therapies are being tested in the neoadjuvant and adjuvant setting.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Koss LG. Tumors of the urinary bladder. In: Atlas of tumor pathology, 2nd series, fascicle 11. Washington DC: Armed Forces Institute of Pathology; 1975.
Johansson SL, Anderstrom CR. Primary adenocarcinoma of the urinary bladder and urachus. In: Raghavan D, Brecher MI, Johnson DH, Meropol NJ, Moots PJ, Thigpen JT, editors. Textbook of uncommon cancer. New York/Chichester: Wiley-Liss; 1999. p. 29–43.
Sternberg CN, Swanson DA. Non-transitional cell bladder cancer. In: Raghavan D, Scher HI, Leibel S, Lange PH, editors. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven; 1997. p. 315–30.
Brown JL, Russell PJ, Philips J, Wotherspoon J, Raghavan D. Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity. Br J Cancer. 1990;61:369–76.
Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–72.
Bostwick DG, Montironi R, Lopez-Beltran A, Cheng L. Pathology of urothelial tumors of the bladder. In: Droller MJ, editor. American cancer society atlas of clinical oncology – urothelial tumors. London/Hamilton: BC Decker Inc; 2004. p. 92–111.
Ro JY, Ayala AG, El-Naggar A. Muscularis mucosa of urinary bladder: importance for staging and treatment. Am J Surg Pathol. 1987;11:668–73.
Slack NH, Prout Jr GR. The heterogeneity of invasive bladder carcinoma and different responses to treatment. J Urol. 1980;123:644.
Mameghan H, Fisher RJ, Watt WH, et al. The management of invasive transitional cell carcinoma of the bladder: results of definitive and preoperative radiation therapy in 390 patients treated at the Prince of Wales Hospital, Sydney, Australia. Cancer. 1992;69:2771.
Gospodarowicz MK, Hawkins NV, Rawlings GA, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol. 1989;142:1448.
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19:666–75.
Gustafson H, Tribukait B, Esposti PL. DNA profile and tumour progression in patients with superficial bladder tumours. Urol Res. 1982;10:13.
Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. N Engl J Med. 1990;322:1129–33.
Russell PJ, Brown JL, Grimmond SM, Raghavan D. Molecular biology of urological tumors. Br J Urol. 1990;65:121–30.
Limas C, Lange PH, Fraley EE, Vessella RL. ABH antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course. Cancer. 1979;44:2099–107.
Spruck III CH, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54:784–8.
Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259–64.
Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A. 1990;97:9047–51.
Theodorescu D, Sapinoso LM, Conaway MR, et al. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 2004;10(11):3800–6.
Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998;58:1090–4.
Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90:1072–9.
Tamimi Y, Bringuier PP, Smit F, et al. Homozygous deletions of p16(INK4) occur frequently in bilharziasis-associated bladder cancer. Int J Cancer. 1996;65:840–5.
Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985;1:366–8.
Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer. 1994;69:1120–5.
Seymour GJ, Walsh MD, Levin MR, Strutton G, Gardiner RA. Transferrin receptor expression by human bladder transitional cell carcinoma. Urol Res. 1987;15:341–4.
Bochner B, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87:1603–12.
Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst. 1997;89:219–27.
Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778–89.
Meyers FJ, Palmer JM, Freiha FS, et al. The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study. J Urol. 1984;134:1118–21.
Pendyala L, Velagapudi S, Toth K, Glaves D, Creaven PJ, Raghavan D. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res. 1997;3:793–8.
Cote RJ, Esrig D, Groshen S, et al. P53 and treatment of bladder cancer. Nature. 1997;385:123–4.
Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145:459–67.
Sarkis A, Bajorin D, Reuter V, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995;13:1384–90.
Siu LL, Banerjee D, Khurana RJ, et al. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle invasive urothelial transitional cell carcinoma. Clin Cancer Res. 1998;4:559–65.
Kelley SL, Basu A, Teicher BA, et al. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988;241:1813–5.
Satoh M, Kloth DM, Kadhim SA, et al. Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis. Cancer Res. 1993;53:1829–32.
Kielb SJ, Shah NL, Rubin MA, Sanda MG. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. J Urol. 2001;166:482–7.
Petrylak DP, Scher HI, Reuter V, O'Brien JP, Cordon-Cardo C. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol. 1994;3:835–40.
Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11:2625–36.
Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62:309–17.
Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder, based on P53 status. J Clin Oncol. 2011;29:3443–9.
Barnes RW, Dick AL, Hadley HL, Johnston OL. Survival following transurethral resection of bladder carcinoma. Cancer Res. 1977;37:2895–7.
Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol. 1987;138:1162.
Holzbeierlein JM, Lopez-Corona E, Bochner BH, Herr HW, Donat SM, Russo P, Dalbagni G, Sogani PC. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol. 2004;172:878–81.
Solsona E, Iborra I, Dumont R, Rubio J, Casanova JL, Almenar S. Risk groups in patients with bladder cancer treated with radical cystectomy: statistical and clinical model improving homogeneity. J Urol. 2005;174:1226–30.
Lee CT, Madii R, Daignault S, Dunn RL, Zhang Y, Montie JUE, Wood Jr DP. Cystecotmy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 2006;175:1262–7.
Rozet F, Harmon J, Arroyo C, Cathelineau X, Barret E, Vallancien G. Benefits of laparoscopic prostate-sparing radical cystectomy. Expert Rev Anticancer Ther. 2006;6:21–6.
Pinthus JH, Nam RK, Klotz LH. Prostate sparing radical cystectomy – not for all, but an option for some. Can J Urol. 2006;(Vol. 13 Suppl 1):81–7.
McBain CA, Logue JP. Radiation for muscle-invasive bladder cancer: treatment planning and delivery in the 21st century. Semin Radiat Oncol. 2005;15:42–8.
Shipley WU, Prout Jr GR, Kaufman DS, Peronne TL. Invasive bladder carcinoma: the importance of initial transurethral surgery and other significant prognostic factors for improved survival with full-dose irradiation. Cancer. 1987;60:514–20.
Parsons JT, Million RR. The role of radiation therapy alone or as an adjunct to surgery in bladder carcinoma. Semin Oncol. 1990;17:566–82.
Michaelson MD, Shipley WU, Heney NM, Zietman AL, Kaufman DS. Selective bladder preservation for muscle invasive transitional cell carcinoma of the urinary bladder. Br J Urol. 2004;90:578–81.
Lotz HT, Pos FJ, Hulshof MC, van Herk M, Lebesque JV, Duppen JC, Remeijer P. Tumor motion and deformation during external radiotherapy of bladder cancer. Int J Radiat Oncol Biol Phys. 2006;64:1551–8.
Horwich A, Dearnaley D, Huddart R, Graham J, Bessell E, Mason M, Bliss J. A randomized trial of accelerated radiotherapy for localized invasive bladder cancer. Radiother Oncol. 2005;75:34–43.
Nieuwenhuijzen JA, Pos F, Moonen LM, Hart AA, Horenblas S. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol. 2005;48:239–45.
Raghavan D, Stein JP, Cote R, Jones JS. Bladder cancer. In: Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, editors. Holland-Frei cancer medicine 8. Shelton: PMPH; 2010. p. 1219–27.
Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14:2901–7.
James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–88.
International Collaboration of Trialists on behalf of MRC Advanced Bladder Cancer Working Party, EORTC Genitourinary Group, Australian Bladder Cancer Study Group, et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. Lancet. 1999;354:533–40.
Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar M for International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171–7.
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood Jr DP, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.
Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927–34.
Shipley WU, Winter K, Kaufman D, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16:3576–83.
Lehman J, Franzaring L, Thuroff J, Wellek S, Stockle M. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int. 2006;97:42–7.
Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996;155:495–500.
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48:189–201.
von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.
Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:1107–13.
Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. Proc Am Soc Clin Oncol. 2010, abstract LBA4518.
Pruthi RS, Nielsen M, Heathcore S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 2010;106:349–54.
David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007;178:451.
Porter MP, Kerrigan MC, Donato BM, Ransey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2011;29:252–8.
Miles BJW, Fairey AS, Eliasziw M, et al. Referral and treatment rates of neoadjvuant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J. 2010;4:263–7.
Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer. 2011;117:276–82.
Dancik G, Aisner D, Theodorescu D. A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. PLoS Curr. 2011;3:RRN 1248.
Sjodahl G, Lauss M, Lovgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18:3377–86.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag London
About this chapter
Cite this chapter
Raghavan, D., Sandler, H.M. (2015). Invasive Bladder Cancer: Combined Modality Treatment. In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_34
Download citation
DOI: https://doi.org/10.1007/978-0-85729-482-1_34
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-481-4
Online ISBN: 978-0-85729-482-1
eBook Packages: MedicineMedicine (R0)